![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BERNA ENTERS PARTNERSHIPS WITH CSL, APOXIS
BERNA ENTERS PARTNERSHIPS WITH CSL, APOXIS
June 27, 2005
Berna Biotech AG said it has entered into two new partnerships, one with Australian group CSL and the other with Swiss company Apoxis SA. With CSL, the Swiss biotech group has signed an exclusive commercialisation and licence agreement to sell its Aerugen treatment in Australia and New Zealand. Aerugen is a vaccine for the prophylaxis of pseudomonas aeruginosa infections in cystic fibrosis patients and is expected to be launched in Europe in the year 2007.
Forbes (http://www.forbes.com/home/feeds/afx/2005/06/22/afx2105106.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct